The Medical Letter on Drugs and Therapeutics
Azilsartan Medoxomil (Edarbi) - The Eighth ARB
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The angiotensin receptor blocker (ARB) azilsartan medoxomil (Edarbi – Takeda) was recently approved by the FDA for oral treatment of hypertension, either alone or combined with other drugs. It is the eighth ARB approved for this indication.

ARBs — ARBs are widely used for treatment of hypertension; they are generally as effective as ACE inhibitors in reducing blood pressure, and are better tolerated. It is unclear whether all ARBs are clinically equivalent; some have been shown to improve clinical outcomes in patients with cardiovascular disease or diabetes. Losartan (Cozaar, and others) is currently the only ARB available generically.1

CLINICAL STUDIES — The approval of azilsartan was based on 7 randomized, double-blind trials in almost 6000 patients with hypertension. One study in 1291 patients found that 80 mg of azilsartan ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Azilsartan Medoxomil (Edarbi) - The Eighth ARB
Article code: 1364c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian